-
Moderna Gets A 'Booster' Shot: Why Stock Is Up Nearly 7% Today
Wednesday, January 18, 2023 - 7:34am | 442Moderna, Inc. (NASDAQ: MRNA) shares were solidly higher in premarket trading on Wednesday. What Happened: The upside in Moderna’s shares comes in reaction to a clinical readout announced late Tuesday, which showed that the Cambridge, Massachusetts-based company’s mRNA vaccine targeting...
-
Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock
Wednesday, September 28, 2022 - 12:35am | 531Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate. What Happened: Biogen and Eisai said the global Phase 3 confirmatory study, "Clarity...
-
Moderna Rallies After Q4 Earnings: What 2 Analysts Have To Say About COVID-19 Stock
Thursday, February 24, 2022 - 5:47pm | 609Moderna, Inc. (NASDAQ: MRNA) reported better-than-expected fourth-quarter earnings Thursday and announced a slight upward revision to its vaccine sales forecast for 2022. The company also announced a $3-billion stock buyback. The stock rallied 15.1% in Thursday's trading session. Here's...
-
How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
Thursday, December 23, 2021 - 4:01pm | 671Pfizer, Inc. (NYSE: PFE) announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration. The Pfizer Analysts: SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer. BofA...
-
Pfizer's COVID-19 Franchise Could Push Revenue Past $100B In 2022: Analyst
Tuesday, November 23, 2021 - 3:16pm | 614Pfizer, Inc. (NYSE: PFE) found huge success with its COVID-19 franchise that includes Comirnaty, the COVID-19 vaccine it co-developed with BioNTech SE (NASDAQ: BNTX), and its yet-to-be authorized oral COVID-19 pill Paxlovid. The Pfizer Analyst: SVB Leerink analyst Geoffrey Porges reiterated a...
-
Why InflaRx Shares Are Ripping Higher Thursday
Thursday, October 28, 2021 - 9:51am | 393InflaRx N.V. (NASDAQ: IFRX) shares are rallying hard Thursday. Here's why. What Happened: German biopharma InflaRx, which focuses on developing therapies for autoimmune and inflammatory diseases, announced positive data Wednesday from the third cohort of patients in the Phase 2a study...
-
Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism
Monday, September 27, 2021 - 12:01pm | 436Sanofi SA (NASDAQ: SNY) shares traded higher by 0.4% on Monday after the company scored an analyst upgrade. The Analyst: SVB Leerink analyst Geoffrey Porges upgraded Sanofi from Market Perform to Outperform and raised his price target per U.S. ADR from $69.61 to $71.37. Related Link: Cigna Has...
-
Why Did SVB Leerink Initiate Humana With Outperform?
Monday, September 27, 2021 - 10:40am | 315While Humana Inc.’s (NYSE: HUM) stock already seems to price in the near-term concerns around rebounding medical costs and high COVID-19 costs, it offers an opportunity to gain exposure to “the post-COVID accelerating growth environment and associated 2022 inflection,” according...
-
What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict
Wednesday, July 14, 2021 - 5:04pm | 783FibroGen, Inc. (NASDAQ: FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat. The committee is scheduled to meet between 9:30 a.m. and 5:30 p.m. Roxadustat was ...
-
Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know
Wednesday, July 7, 2021 - 3:02pm | 275Biohaven Pharmaceutical Ltd. (NYSE: BHVN) released preliminary second-quarter revenue data for its drug Nurtec ODT on Wednesday. What Happened: Nurtec achieved preliminary net product revenue of approximately $93 million in the second quarter, according to the company. Since its launch in March...
-
5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing
Tuesday, June 8, 2021 - 12:51pm | 1150Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over 38%. The Biogen Analysts: Morgan Stanley analyst Matthew Harrison maintained an Overweight rating on Biogen shares and increased the price target from...
-
After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers
Tuesday, April 6, 2021 - 5:36pm | 694ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares came under pressure Monday after the Food and Drug Administration (FDA) rejected its regulatory application seeking label expansion for its dementia drug. The Acadia Analysts: Goldman Sachs analyst Salveen Richter downgraded Acadia shares...
-
Cathie Wood Is Bullish On 908 Devices. An Analyst Makes A Case For The Stock
Wednesday, March 31, 2021 - 4:39am | 427908 Devices Inc (NASDAQ: MASS) is seen as a high-growth life science tools company that analysts at SVB Leerink expect to “outperform” despite conservative 2021 guidance given by its management due to the current visibility. The 908 Devices Analyst: SV Leerin analyst Puneet Souda has...
-
Breaking Down Novavax's Coronavirus Vaccine Data: 2 Analyst Takes
Friday, January 29, 2021 - 4:36pm | 833Novavax, Inc. (NASDAQ: NVAX) shares were roaring higher Friday after the company reported topline results from the late-stage trial of its coronavirus vaccine candidate in the U.K. The Novavax Analyst: H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating and $207 price target for...
-
Imara Analyst Says Buy The Weakness Ahead Of Multiple 2021 Data Readouts
Wednesday, January 6, 2021 - 6:21pm | 324Imara Inc (NASDAQ: IMRA) shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease. Underwhelming Data: IMR-687 failed to close part of the gap from the 1.7% absolute increase in fetal hemoglobin, or HbF, demonstrated at interim readout and...